skip navigation


Home » Resources » Clinical Studies » A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old

Clinical Studies Supported by the NEI

A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old

Purpose | Background | Description | Patient Eligibility | Patient Recruitment Status | Current Status of Study | Results | Publications | NEI Representative | Resource Centers

Purpose:

  • To report the success proportions of simple probing within different age groups of patients under 24 months of age.
  • To obtain descriptive data regarding symptoms and quality of life in patients receiving simple probing.
  • To obtain similar data for simple probing in patients 24 months of age or older, for intubation in patients age 6 - <48 months, and for balloon catheter dilation in patients age 6 - <48 months.

Background:

Nasolacrimal duct obstruction (NLDO) is a common ocular condition in the first year of life. Most cases will resolve spontaneously or with massage. Many studies of primary treatment of nasolacrimal duct obstruction have been reported. These case series have largely been retrospective, uncontrolled, and conducted in single centers.

Simple probing is the most widely-used initial treatment for NLDO in infancy. Two differing approaches to simple probing have been most often been used, immediate office probing (early probing-generally after 6 months of age), and medical management (episodic antibiotic drops with massage of the lacrimal sac) until 9-13 months of age followed by probing under general anesthesia (late probing). The possible advantages of early probing are the avoidance of general anesthesia, immediate resolution of symptoms, lesser cost, and prevention of fibrosis from inflammation in the nasolacrimal duct. The advantages of late probing include more comfort with the procedure and the avoidance of the procedure completely. Both early and late probing approaches are usually successful for treatment of NLDO in patients under 2 years of age, with reported success proportions varying from between 54% to 98%. Although a number of studies have found that probing was highly successful and without an age-related decline until at least 4 years of age and beyond, there is a suspicion among other clinicians of a clinically-important decline in the success proportions among progressively older age groups of preschool children. A large prospective interventional case series might help to clarify whether there is an age-related decline in success.

Balloon catheter dilation has become popular for the initial surgical treatment of NLDO especially in children older than one year. This procedure involves probing of the nasolacrimal duct with a semiflexible wire probe with an inflatable balloon on the tip.

Nasolacrimal intubation has been used for primary treatment by clinicians in older children or when the duct feels tight. While generally successful, there is less certainty of the success proportions for this procedure when performed as a primary treatment. It is also unknown how often this procedure is used for initial treatment.

Probing of the nasolacrimal duct for the repair of NLDO is a very successful procedure in infancy and childhood. Simple probing has long been the standard approach, though the age at which the procedure declines in effectiveness is controversial. Clinicians have been urged by manufacturers of medical equipment to consider intubation and balloon dilation even in the age range in which probing is highly successful, to further increase the chance of success.

A prospective non-randomized study of the outcomes from many centers of all strategies might allow better estimates of success for the techniques most often used over an extended age range. Such a study might help to define factors associated with failure of each of the techniques.

Description:

The study has been designed as an observational study that approximates standard clinical practice. All procedures are consistent with standard care with the exception of a questionnaire which the patient's parent will complete at each study visit on NLDO symptoms and quality of life. The surgical center is not engaged in the research and no data will be collected by surgical personnel.

Treatment success is defined as the absence of any clinical signs of nasolacrimal duct obstruction: presence of epiphora, increased tear film, or mucous discharge.

Patient Eligibility:

Patients undergoing a primary procedure for NLDO will be enrolled at an institution-based or community-based clinic by investigators in the PEDIG study group who have elected to participate in the study.

Major Eligibility Criteria for the Patient

  • Age 6 - < 48 months
  • Parent/guardian has the ability to complete a written questionnaire
  • For patients with two eyes requiring surgery at enrollment: investigator is planning to perform the same type of surgical procedure on both eyes

Major Eligibility Criteria for the Study Eye(s)

  • Onset of NLDO symptoms and/or signs prior to 6 months chronological age
  • Presence of epiphora, increased tear film, and/or mucopurulent discharge in the absence of an upper respiratory infection or an ocular surface irritation
  • No history of nasolacrimal duct surgery including simple probing, nasolacrimal intubation, balloon catheter dilation, or dacryocystorhinostomy
  • Undergoing primary NLDO surgery

For patients enrolling with bilateral NLDO who are undergoing a first procedure on both eyes, both eyes will be enrolled in the study if both meet eligibility criteria.

Patient Recruitment Status:

No longer recruiting. Comments:

Current Status of Study:

Completed, with results not yet published. Comments: The study was completed in September 2006.

Results:

None

Publications

None

NEI Representative



Donald F. Everett, M.A.
National Eye Institute
National Institutes of Health
Suite 1300
5635 Fishers Lane MSC 9300
Bethesda, MD 20892-9300
USA
Telephone: (301) 451-2020
Fax: (301) 402-0528
Email: deverett@nei.nih.gov

Resource Centers


Data Coordinating Center
Roy W. Beck, M.D., Ph.D.
Pamela S Moke, M.S.P.H.
Gladys N. Bernett, M.B.A., M.H.A.
Nicole M. Boyle
Esmeralda L. Cardosa
Danielle Chandler, M.S.P.H.
Laura Clark
Allison Edwards, M.S.
Heidi A. Gillespie
Raymond T. Kraker, M.S.P.H.
Michele Melia
Christina M. Morales
Jaeb Center for Health Research
15310 Amberly Drive
Suite 350
Tampa, FL 33647
USA
Telephone: (813) 975-8690
Fax: (813) 975-8761
Email: pedig@jaeb.org
URL: PEDIG Website

PEDIG Co-Chairman
Michael X. Repka, M.D.
Wilmer Eye Institue
Johns Hopkins University School of Medicine
600 N. Wolfe Street
Baltimore, MD 21287-9028
USA
Telephone: (410) 955-8314
Fax: (410) 955-0809
Email: mrepka@jhmi.edu

PEDIG Co-Chairman
Jonathan M. Holmes, M.D.
Mayo Clinic
Department of Ophthalmology W7
200 First Street Southwest
Rochester, MN 55905
USA
Telephone: (507) 284-3760
Fax: (507) 284-8566
Email: holmes.jonathan@mayo.edu

Last Updated: 11/13/2007

 

Bookmark or share this page


U. S. Department of Health and Human Services

National Institutes of Health

USA.gov